NICE now recommends capivasertib, also known as truqap and made by Astra Zeneca, with fulvestrant for those with HR positive HER2 negative metastatic breast cancer with certain genetic mutations after endocrine or hormone therapy. Capivasertib tablets are to be taken twice a day to block the action of an abnormal protein that tells cancer cells to multiply.
Secondary1st
Seeking a cure for secondary breast cancer
